New Funding from Solve M.E. Accelerates Innovative Research for ME/CFS and Long Covid Treatments

New Research Initiatives from Solve M.E.

In a significant development for the fields of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Covid, Solve M.E. has introduced new funding aimed at accelerating research in these complex conditions. Announced on World ME Awareness Day, the initiative seeks to overcome the barriers that these disorders present, particularly in areas of diagnostics and treatment options.

Addressing a Critical Need

Both ME/CFS and Long Covid are debilitating conditions, characterized by severe fatigue, cognitive difficulties, and a range of other debilitating symptoms. Millions of individuals are affected globally, yet they are left with limited support due to the ongoing lack of FDA-approved treatments and definitive diagnostic tests. The gap in research funding has further compounded this issue, making the work of organizations like Solve M.E. critical.

To combat this, the organization has established the Catalyst Awards, which are specifically designed to ensure promising research does not stagnate due to financial constraints. Two major research projects have been awarded funding under this program, marking an important step forward in understanding and treating these conditions.

The Catalyst Award-Winning Studies

1. Mitochondrial Stabilizer IVO-21

Led by Dr. Jay H. Chung from the National Institutes of Health, this project focuses on a low-cost pill called IVO, which is being tested in preclinical models. Its aim is to enhance cellular energy levels while reducing inflammation, two factors believed to play a crucial role in the symptoms experienced by people with ME/CFS and Long Covid. This study represents a potential breakthrough in paving the way for accessible treatments that tackle the root of these complex diseases.

2. Sequence ME - Long Covid

Managed by a team including Prof. Chris Ponting and Sonya Chowdhury, this project expands on a large-scale genetic study utilizing whole-genome sequencing to scrutinize the entire 3 billion genetic positions in participants. This approach offers 3,000 times more data compared to standard measures and aims to identify new biomarkers that could lead to effective therapies for ME/CFS and Long Covid. The research team hopes this detailed genetic analysis unveils factors connected to disease risk and fosters breakthroughs in both diagnosis and treatment.

A Commitment to Patient Advocacy

Emily Taylor, President and CEO of Solve M.E., emphasized the organization's dedication to bridging the gap between research and clinical trials. The Catalyst Award efforts underscore Solve M.E.'s commitment to centering patient experiences and addressing the real-life complexities of living with these debilitating conditions. The DecodeME management team echoed this sentiment, highlighting that the funding is instrumental in mobilizing crucial studies to further understand the biological underpinnings of ME/CFS and Long Covid.

Looking Ahead

The Catalyst Awards not only represent pivotal funding but also illustrated the organization’s philosophy of prioritizing studies that have already shown promise in advancing understanding of ME/CFS and Long Covid. As they bridge funding gaps, they ensure that vital research continues to move forward, setting the stage for impactful trials, publications, and advancements in the field.

Solve M.E. is also set to host free educational webinars where researchers will share their findings and insights related to their work. These discussions will provide an opportunity for both the scientific community and the public to engage with and learn more about the ongoing efforts to combat these challenging conditions.

To find out more about these research studies or to support Solve M.E., visit SolveME.org.